Bringing you essential updates from the American Heart Association (AHA) Scientific Sessions is the AHA Action Center. Here you’ll find in-depth discussions and analyses on the latest research, management guidelines, and innovations in cardiology, directly from leading experts in the field featured at the 2024 conference.
Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
